Physician profile
Johnny Fraley
NPI 1427666460
$4,256.42
in general payments reported to CMS, 2019-2025
24 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,039 · 2022: $333 · 2023: $1,977 · 2024: $510 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Travel and Lodging: $886 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.66 |
| Travel and Lodging | $885.87 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,454.35 | 2023 | |
| Novartis Pharmaceuticals Corporation | $543.24 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $426.58 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $390.19 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $318.64 | 2021-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $194.81 | 2021-2022 | |
| Biosense Webster, INC. | $164.97 | 2023-2025 | Carto 3 |
| Merck Sharp & Dohme LLC | $125.98 | 2022-2025 | Zerbaxa |
| Amgen INC. | $119.50 | 2021-2024 | Repatha |
| Boston Scientific Corporation | $109.73 | 2024-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.17 | 2021-2022 | |
| Pfizer INC. | $53.56 | 2021-2023 | |
| Organogenesis INC. | $34.53 | 2025 | Puraply Wound Matrix |
| Cvrx, INC. | $30.53 | 2024 | Barostim Neo System |
| Advanced Oxygen Therapy INC. | $29.00 | 2025 | Topical Oxygen Chamber For Extremities |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $26.75 | 2025 | Collagenase Santyl |
| Kowa Pharmaceuticals America, INC. | $26.45 | 2021 | |
| Edwards Lifesciences Corporation | $24.79 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daxor Corporation | $21.28 | 2024 | Bva-100 |
| Abbott Laboratories | $19.79 | 2022 | |
| Amarin Pharma, INC. | $19.44 | 2021 | |
| Hartmann USA, INC. | $16.55 | 2025 | Zetuvit Plus 10x10 P10 |
| Solventum Corporation | $15.37 | 2025 | Activ.A.C. |
| Hollister Incorporated | $15.22 | 2025 | Adapt Ceraring |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Fraley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.